Veracyte, Inc. , a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical ...

Intelligently searches through manuals, troubleshooting guides, and service history to answer technician questions and proactively recommend service resolutions ...

Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...

In this article, we are going to take a look at where Sarepta Therapeutics ... Growth is expected to be fueled by increased utilization and new therapy launches, says McKinsey.

By way of learning-by-doing, we'll look at ROE to gain a better understanding of Sarepta Therapeutics ... year profits (retained earnings), issuing new shares, or borrowing.

Read Our Latest Stock Report on SRPT Sarepta Therapeutics Stock Down 0.3 % Shares of NASDAQ SRPT opened at $111.82 on Thursday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high ...

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sarepta Therapeutics SRPT has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...